Acorda/Biogen Idec's Ampyra becomes first US FDA-approved drug to improve walking in MS
This article was originally published in Scrip
Executive Summary
The US FDA has approved Acorda Therapeutics/Biogen Idec's oral drug Ampyra (dalfampridine; formerly fampridine SR) to improve walking in patients with multiple sclerosis, making it the first drug to be approved for the management of specific symptoms of the disease.